Shares of China's CanSino Biologics rise as much as 15% on W...
Shares of China's CanSino Biologics rise as much as 15% on Wednesday afternoon. Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable.